Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Tracy T. Chow, Michael Amatangelo, Peilin Ma, Chad C. Bjorklund, Krista Wollerman, Tiziana Civardi, Phillip Koo, Yue Zhu, Paulo Maciag, Jessica Katz, Aparna Raval, Albert Oriol, Robert Z. Orlowski, Darrell White, Paul G. Richardson, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3318.

https://doi.org/10.1182/blood-2023-178881

Published: 2023

Journal Articles

RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects

Michael Amatangelo, Erin Flynt, Nicholas Stong, Maria Ortiz, Pradipta Ray, Maria Wang, Niels W.C.J. van de Donk, Sagar Lonial, Aparna Raval, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 4665.

https://doi.org/10.1182/blood-2023-178912

Published: 2023

Journal Articles

Biomarker Analysis of a Phase Ia/Ib Open-Label, Multicentre Study of Tiragolumab or Tiragolumab + Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Shannon Ruppert, Vaikunth Cuchelkar, Raymond Meng, Eunpi Cho, Sean Lear, Cheryl Victoria Wong, Aparna Raval, Yann Nouet

Blood (2021) 138 (Supplement 1): 1337.

https://doi.org/10.1182/blood-2021-147773

Published: 2021

Journal Articles

Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)

Aparna Raval, Habib Hamidi, Olivia Hwang, Cherie Green, Catarina Maia, Marta Lasa, Maika Onishi, Paula Rodriguez-Otero, Jesús F. San-Miguel, Jorge D. Gallo, Bruno Paiva, PhD, Fredrik Schjesvold, MDPhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134910

Published: 2020

Journal Articles

Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma

Fredrik Schjesvold, Vincent Ribrag, MD, Paula Rodriguez-Otero, MD PhD, Pawel J. Robak, MDPhD, Markus Hansson, MD, Roman Hajek, Adrián Alegre Amor, MD PhD, Joaquin Martinez-López, Maika Onishi, Jorge D. Gallo, Aparna Raval, Sameer Deshpande, Vikram Malhi, Wan-Jen Hong, MD, Marc S. Raab, MD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-135845

Published: 2020

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

Elisabeth A Lasater, PhD, An D Do, Luciana Burton, Yijin Li, Erin Williams, Jason Oeh, Luciana Molinero, Elicia Penuel, Deepak Sampath, Monique Dail, Marcia Belvin, Teiko Sumiyoshi, Elizabeth A Punnoose, Jeffrey Venstrom, Aparna Raval

Blood (2018) 132 (Supplement 1): 1118.

https://doi.org/10.1182/blood-2018-99-116405

Published: 2018

Journal Articles

Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells

Le Xuan Truong Nguyen, Steven M. Chan, Tri Duc Ngo, Aparna Raval, Kyeong Kyu Kim, Ravindra Majeti, Beverly S. Mitchell

Blood (2014) 124 (4): 579–589.

https://doi.org/10.1182/blood-2013-12-544726

Published: 2014

Includes: Supplemental data

Journal Articles

Reduced rRNA expression and increased rDNA promoter methylation in CD34 + cells of patients with myelodysplastic syndromes

Aparna Raval, Kunju J. Sridhar, Shripa Patel, Brit B. Turnbull, Peter L. Greenberg, Beverly S. Mitchell

Blood (2012) 120 (24): 4812–4818.

https://doi.org/10.1182/blood-2012-04-423111

Published: 2012

Includes: Supplemental data

Journal Articles

Reactivation of Telomerase in Late Generation Tert−/− Mice Results in Reversal of Anemia

Aparna Raval, PhD, Brenda Kusler, BS, Alina Garbuzov, BS, Steven Artandi, MD, PhD, Beverly S. Mitchell

Blood (2012) 120 (21): 1258.

https://doi.org/10.1182/blood.V120.21.1258.1258

Published: 2012

Journal Articles

Defective Hematopoiesis and Erythroid Differentiation Resulting From Telomerase Deficiency

Aparna Raval, PhD, Brenda Kusler, BS, Steven Artandi, MD, PhD, Beverly S. Mitchell, MD

Blood (2011) 118 (21): 2410.

https://doi.org/10.1182/blood.V118.21.2410.2410

Published: 2011

Journal Articles

A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes

Daniel A Pollyea, MD, Aparna Raval, PhD, Brenda Kusler, Jason R Gotlib, MD, MS, Ash A. Alizadeh, MD, PhD, Beverly S. Mitchell, MD

Blood (2010) 116 (21): 1889.

https://doi.org/10.1182/blood.V116.21.1889.1889

Published: 2010

Journal Articles

Ribosomal RNA Expression In CD34+ Hematopoietic Progenitor Cells Inversely Correlates with Ribosomal DNA Methylation In Myelodysplastic Syndromes.

Aparna Raval, PhD, Daniel A Pollyea, MD, Kunju J Shridhar, PhD, Shripa Patel, Peter L. Greenberg, MD, Beverly S. Mitchell, MD

Blood (2010) 116 (21): 1682.

https://doi.org/10.1182/blood.V116.21.1682.1682

Published: 2010

Journal Articles

NPM1 Haploinsufficiency Results in Increased Numbers of Hematopoietic Stem Cells and Progenitor Cells.

Aparna Raval, Christopher Y. Park, Wendy W Pang, Brenda Kusler, Kunju Joshi Sridhar, Jason R Gotlib, Peter L Greenberg, Irving L. Weissman, Beverly S. Mitchell

Blood (2009) 114 (22): 738.

https://doi.org/10.1182/blood.V114.22.738.738

Published: 2009

Journal Articles

Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia.

Li Yu, MD., Chunhui Liu, Jeff Vandeusen, Brian Becknell, Zunyan Dai, Yue-Zhong Wu, Aparna Raval, Te-Hui Liu, Wei Ding, Charlene Mao, Shujun Liu, Laura T. Smith, Stephen Lee, Laura Rassenti, Guido Marcucci, John Byrd, Michael A. Caligiuri, MD., Christoph Plass, PhD.

Blood (2004) 104 (11): 3488.

https://doi.org/10.1182/blood.V104.11.3488.3488

Published: 2004

NARROW

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects

Biomarker Analysis of a Phase Ia/Ib Open-Label, Multicentre Study of Tiragolumab or Tiragolumab + Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)

Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells

Reduced rRNA expression and increased rDNA promoter methylation in CD34 + cells of patients with myelodysplastic syndromes

Reactivation of Telomerase in Late Generation Tert−/− Mice Results in Reversal of Anemia

Defective Hematopoiesis and Erythroid Differentiation Resulting From Telomerase Deficiency

A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes

Ribosomal RNA Expression In CD34+ Hematopoietic Progenitor Cells Inversely Correlates with Ribosomal DNA Methylation In Myelodysplastic Syndromes.

NPM1 Haploinsufficiency Results in Increased Numbers of Hematopoietic Stem Cells and Progenitor Cells.

Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only